Bexion Pharmaceuticals
Bexion Pharmaceuticals is a mid-stage clinical company based in Covington, KY, focused on developing innovative treatments for Oncology and CNS, with its lead compound BXQ-350 showing promise in various cancers and chemotherapy-induced peripheral neuropathy.
Company Overview
Bexion Pharmaceuticals is a mid-stage clinical company located at 632 Russell Street, Covington, KY 41011. The company focuses on developing life-changing treatments in Oncology and CNS (Central Nervous System). Bexion Pharmaceuticals is dedicated to advancing scientific research and has a commitment to patient advocacy through collaborations with advocacy partners. Its lead compound, BXQ-350, is central to its clinical development efforts.
Lead Compound: BXQ-350
BXQ-350 is Bexion Pharmaceuticals' leading compound. It is a novel S1P (Sphingosine-1-phosphate) modulator that has shown evidence of anti-tumor activity and a tolerable safety profile without dose-limiting toxicity. BXQ-350's mechanisms of action include S1P reduction properties, modulation of the tumor microenvironment, and elevation of ceramide programmed cell death. It also possesses neuroprotective properties, which may benefit patients with chemotherapy-induced peripheral neuropathy (CIPN).
Clinical Trials and Development
Bexion Pharmaceuticals is pursuing an extensive clinical development plan for BXQ-350. The compound is being investigated for its potential in treating metastatic colorectal cancer (mCRC), malignant glioma, diffuse intrinsic pontine glioma (DIPG), and diffuse midline glioma (DMG). The company has completed enrollment in Phase 1 studies for adults and children with advanced solid tumors using BXQ-350 as monotherapy. Ongoing research and trials aim to confirm the compound's efficacy and safety across these indications.
Orphan Drug Status and Benefits
BXQ-350 has been granted Orphan Drug status for the treatment of malignant glioma, including diffuse intrinsic pontine glioma (DIPG). This status provides several benefits, such as eligibility for research grants, potential tax credits, waiver of FDA application user fees, and a potentially expedited regulatory process. These advantages support Bexion Pharmaceuticals in conducting further research and development to bring the therapy to market efficiently.
Commitment to Patient Advocacy
Bexion Pharmaceuticals prioritizes patient advocacy and works closely with patient organizations and advocacy partners. The company's collaborations aim to align its development priorities with the needs of patients and their families within the oncology community. This commitment is reflected in Bexion's focus on developing therapies for pediatric cancers, including DIPG and DMG, and supporting patients through their treatment journey.